Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- LUMO
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Lumos Pharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 37.54M
- Ent value
- 36.56M
- Price/Sales
- 17.02
- Price/Book
- 7.64
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -20.27%
- 1 year return
- 48.63%
- 3 year return
- -16.22%
- 5 year return
- -22.46%
- 10 year return
- -35.26%
Last updated: 2025-09-15
DIVIDENDS
LUMO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 17.02 |
| Price to Book | 7.64 |
| EV to Sales | 16.58 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 8.65M |
| EPS (TTM) | -4.19 |
| FCF per share (TTM) | -5.39 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.21M |
| Gross profit (TTM) | 2.18M |
| Operating income (TTM) | -36.33M |
| Net income (TTM) | -34.92M |
| EPS (TTM) | -4.19 |
| EPS (1y forward) | -1.96 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 99.00% |
| Operating margin (TTM) | -1647.57% |
| Profit margin (TTM) | -1583.49% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 13.52M |
| Net receivables | 174.00K |
| Total current assets | 17.27M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 187.00K |
| Total assets | 17.46M |
| Accounts payable | 1.46M |
| Short/Current long term debt | 172.00K |
| Total current liabilities | 6.50M |
| Total liabilities | 12.55M |
| Shareholder's equity | 4.91M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -31.67M |
| Capital expenditures (TTM) | 26.41M |
| Free cash flow (TTM) | -44.88M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -710.54% |
| Return on Assets | -199.97% |
| Return on Invested Capital | -692.23% |
| Cash Return on Invested Capital | -889.73% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| LUMO | S&P500 | |
| Current price drop from All-time high | -99.15% | -0.06% |
| Highest price drop | -99.72% | -56.47% |
| Date of highest drop | 18 Jul 2024 | 9 Mar 2009 |
| Avg drop from high | -70.57% | -10.99% |
| Avg time to new high | 44 days | 12 days |
| Max time to new high | 2435 days | 1805 days |
COMPANY DETAILS
Marketcap
37.54M
Marketcap category
Small-cap
Description
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas. As of December 12, 2024, Lumos Pharma, Inc. was taken private.
Employees
30
Website
Investor relations
-
SEC filings
CEO
Richard J. Hawkins
Country
USA
City
Austin
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner